



Glycan-Dependent Corneocyte Adherence of *Staphylococcus epidermidis* Mediated by the Lectin Subdomain of Aap

Paroma Roy,^a  Alexander R. Horswill,^b  Paul D. Fey^a

^aDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska, USA

^bDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, Colorado, USA

ABSTRACT *Staphylococcus epidermidis* and other coagulase-negative staphylococci (CoNS) that colonize skin are known to promote skin immunity and inhibit colonization of pathogens that cause skin and soft tissue infections, including *Staphylococcus aureus*. However, *S. epidermidis* adherence to corneocytes, the cells that constitute the uppermost layer of the skin epidermis, remains poorly understood. Our study documents that *S. epidermidis* corneocyte adherence is dependent upon the accumulation-associated protein (Aap). Aap is composed of two distinct A and B domains. The A domain is comprised of a repeat region and a conserved L-type lectin domain, whereas the fibrillar B domain, which is comprised of G5 and E repeats, is linked to the cell wall in a sortase-dependent manner. Our studies revealed that adherence to corneocytes is dependent upon the lectin subdomain within the A domain. However, significant adherence was only observed when the lectin domain was expressed with both the A repeat and the B domain, suggesting further interactions between these three domains. Our data also suggest that the A repeat domain is important for stability or expression of Aap. Deglycosylation treatment suggested that glycans expressed in the host stratum corneum serve as potential binding partners for Aap-mediated corneocyte adherence. Last, bioinformatic analyses of the predominant commensal species of CoNS identified open reading frames (ORFs) homologous to *aap*, thus suggesting that Aap orthologues containing lectin-like domains may provide the basis for staphylococcal colonization of skin. Corroborating these observations, adherence to corneocytes in an *S. aureus mgrA* mutant was dependent upon SasG, the Aap orthologue in *S. aureus*.

IMPORTANCE *Staphylococcus aureus* is the most significant cause of skin and soft tissue infections yet it rarely colonizes the skin of healthy individuals. This is believed to be due, in part, to inhibition of colonization via toxic substances produced by normal skin flora, including by *S. epidermidis*. Furthermore, we surmise that *S. aureus* colonization inhibition may also be due to competition for binding sites on host corneocytes. To understand these potential interactions between *S. aureus* and *S. epidermidis* and, potentially, other coagulase-negative staphylococci, we must first understand how staphylococci adhere to corneocytes. This work documents that *S. epidermidis* adherence to corneocytes is dependent upon the fibrillar cell wall-associated protein Aap. Our work further documents that Aap binds to glycans exposed on the corneocyte surface, which are commonly exploited by bacteria to facilitate adherence to host cells. Furthermore, we find that Aap orthologues may be responsible for corneocyte adherence in other staphylococci, including in *S. aureus*.

KEYWORDS accumulation-associated protein, *Staphylococcus aureus*, *Staphylococcus epidermidis*, skin adherence

The skin is our largest and outermost organ and consists of the epidermis, dermis, and subcutaneous tissue. A rich network of epithelial cells, lymphocytes, and antigen-presenting cells populate the epidermis and dermis, facilitating an immune response that

Citation Roy P, Horswill AR, Fey PD. 2021. Glycan-dependent corneocyte adherence of *Staphylococcus epidermidis* mediated by the lectin subdomain of Aap. mBio 12:e02908-20. <https://doi.org/10.1128/mBio.02908-20>.

Invited Editor Lynn E. Hancock, University of Kansas

Editor Michael S. Gilmore, Harvard Medical School

Copyright © 2021 Roy et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Paul D. Fey, pfey@unmc.edu.

Received 27 October 2020

Accepted 28 May 2021

Published 13 July 2021

is vital in wound healing and infection, as well as in modulating the microbiota that colonizes the skin (1). Despite the harsh physical landscape of skin, which is characterized by a desiccated, nutrient-poor, and acidic environment, this organ serves as a complex and dynamic ecosystem for millions of microorganisms. The skin is colonized by many bacterial genera, including *Staphylococcus*, *Corynebacterium*, *Streptococcus*, and *Cutibacterium*, with *Staphylococcus epidermidis* among the most well studied. Other frequent colonizing species of staphylococci include *Staphylococcus hominis*, *Staphylococcus haemolyticus*, *Staphylococcus capitis*, *Staphylococcus lugdunensis*, and *Staphylococcus warneri*, among 38 other identified species of coagulase-negative staphylococci (CoNS) (2–5). However, in certain contexts, including the state of immune activation or host genetic predisposition, skin microbial communities can be remodeled over time or in response to environmental challenges (6–8). Many common skin pathologies are associated with changes in the microbiota, and the state of dysbiosis may contribute to the disruption of immune homeostasis and increase disease symptomatology.

Recent studies have documented that *S. epidermidis* and other CoNS function to protect against invading foreign pathogens, including *Staphylococcus aureus*, thus behaving as mutualists. Indeed, *S. epidermidis* has been shown to inhibit *S. aureus* nasal colonization and biofilm formation through production of the serine protease Esp (9) and subsequent degradation of *S. aureus* surface proteins and host receptors that are crucial for host-pathogen interactions (10). In a more recent study, it was shown that *Staphylococcus lugdunensis* inhibited *S. aureus* growth through the production of the cyclic peptide antibiotic lugdunin (11). Furthermore, *S. epidermidis* and *S. hominis* can secrete antimicrobial peptides (AMPs) that are able to synergize with the human cathelicidin AMP LL-37 to inhibit the growth of *S. aureus*. Strains producing these AMPs were depleted in individuals with atopic dermatitis (AD), who are frequently colonized with *S. aureus*. Moreover, the topical application of these antimicrobial-producing strains decreased the colonization of *S. aureus* in individuals with AD, demonstrating how dysbiosis of the skin microbiota can lead to disease and further documenting the importance of the beneficial CoNS strains (12). Last, the immune system has evolved closely with resident microorganisms in the skin to allow the maintenance of commensal partners and the elimination of possible pathogens. These skin-resident microbes are critical for establishing skin immune homeostasis. In particular, colonization with *S. epidermidis* has been shown to induce interleukin 17A-positive (IL-17A⁺) CD8⁺ T cells that localize to the epidermis and enhance innate barrier immunity and limit pathogen invasion. This process occurs through the coordinated action of skin-resident dendritic cell subsets and is not associated with inflammation, revealing that tissue-resident cells are poised to sense and respond to any alterations in microbial communities (13, 14).

Adhesion to host tissue is fundamental for bacteria to initiate a successful symbiosis (15). However, a mechanistic understanding of staphylococcal adherence to the skin surface remains poorly understood, and hence the molecular interactions existent at this bacterial-host interface is an area of significant interest. Adherence of *S. aureus* to corneocytes in patients with atopic dermatitis (AD) is promoted by the *S. aureus* surface protein ClfB, in addition to the synthesis of neutrophil extracellular traps (NETs) (16–18). However, AD is an altered skin condition that is complicated by mutations in filaggrin, leading to a loss of functional skin barrier and natural moisturizing factors (19). Indeed, *S. aureus* does not typically adhere to healthy skin, suggesting that ClfB ligands may be more accessible as a result of these pathophysiologic changes. The predominant commensal of the healthy skin, *S. epidermidis*, encodes fewer cell wall-anchored (CWA) surface proteins that function as adhesins (20), perhaps rendering it less able to compete for binding in the AD microenvironment. Many cell wall-anchored proteins of staphylococci are multifunctional, and distinct domains mediate adherence to different ligands and contribute to distinct phenotypes (21, 22). Among these, Aap is the best-studied adhesin factor and is found in approximately 85 to 95% of all *S. epidermidis* isolates, independent of culture source (23, 24). As reviewed by Gotz (25), Aap




FIG 1 Aap facilitates adherence of *Staphylococcus epidermidis* to corneocytes. (A) Sections ($353.6\text{-}\mu\text{m} \times 353.6\text{-}\mu\text{m}$) of the corneocyte adherence disks observed by confocal microscopy at 40×0.6 magnification. Each disk was incubated with green fluorescent protein (GFP) expressing 1457 and mutant strains for 45 min at 37°C to analyze the number of adherent bacteria after washing. (B) Mean numbers (with standard error of the mean [SEM]) of adherent 1457/pCM29 and mutants attached to corneocytes (per $89.8\text{-}\mu\text{m} \times 89.8\text{-}\mu\text{m}$ section) as shown in panel A. Comparisons between individual mutants were performed by two-tailed unpaired Student's *t* test with 95% confidence intervals. ***, $P < 0.0001$.

was first identified by Schumacher-Perdreau et al. in 1994 (26) and was further studied by Hussain and colleagues in 1997 (27). Mitomycin mutagenesis led to the isolation of a biofilm-negative mutant, M7, which lacked a 140-kDa exoprotein (26). Hussain and colleagues found an association between this 140-kDa protein and enhanced biofilm production, and thus it was referred to as the accumulation-associated protein (Aap) (27).

Several studies have demonstrated that Aap is a rod-like fibril extending from the cell that can be observed by electron microscopy (28–30). Bioinformatic analyses suggest that Aap is a multidomain protein that consists of two distinct domains, A and B (31). A similar domain arrangement also exists in SasG, the Aap orthologue in *S. aureus* (22). Following extracellular export directed by the N-terminal signal sequence, the protein is anchored to the cell wall by sortase via the C-terminal LPDTG motif (32). Two independent studies found that the A domain, which is composed of a repeat region and an L-type lectin domain, functions to facilitate adherence to abiotic surfaces (32, 33). Moreover, the N-terminal A domain is subjected to complete or partial proteolytic processing by the SepA metalloprotease (34, 35). This enables dimerization of B repeats on adjacent bacteria, thus facilitating intercellular adhesion and bacterial accumulation (29, 36, 37). The C-terminal B domain is composed of B repeats, each of which

contains a G5 module and an E spacer region. Structural analysis supports a “zinc zipper” model whereby interaction between G5 domains is zinc-dependent (29, 30, 37).

A study conducted by Macintosh et al. investigating *S. epidermidis* colonization of the skin identified Aap as one of the adhesins with a potential function in corneocyte attachment (38). The heterologous expression of Aap on the surface of *Lactococcus lactis* increased corneocyte adhesion 30-fold, suggesting that Aap facilitates adhesion to corneocytes independent of other adhesins. Additionally, the A domain of Aap was implicated in mediating this function, as the recombinant A domain of Aap partially blocked corneocyte binding by *S. epidermidis* NCTC 11047 and other *aap*-positive *S. epidermidis* clinical isolates. Moreover, another adhesin, serine-aspartate repeat-containing protein F (SdrF), has also been shown to bind recombinant proteins keratin 1 and 10, normal human epidermal keratinocytes (NHEKs), and human nasal epithelial cells (HNECs), suggesting a potential function in skin adherence (39).

In this study, we used isogenic mutants to document that *S. epidermidis* Aap mediates adherence to healthy skin. Furthermore, we constructed *S. epidermidis* strains expressing various Aap domains, and, in conjunction with blocking studies, documented that adherence to corneocytes is dependent upon the lectin subdomain within the A domain of Aap. Furthermore, we document that Aap-dependent adherence is significantly reduced following enzymatic cleavage of specific glycan structures present on the corneocytes of healthy skin. Last, we provide evidence of Aap orthologues in other staphylococcal species and document that *S. aureus* adheres to healthy skin in an SasG-dependent manner when *sasG* transcription is derepressed via an *mgrA* mutation.

RESULTS

Identification of the *S. epidermidis* factor responsible for adherence to corneocytes.

To identify the factor(s) responsible for *S. epidermidis* adherence to skin, a corneocyte binding assay was developed and performed with an optical density (OD)-adjusted suspension of different *S. epidermidis* 1457 strains that constitutively express green fluorescent protein (GFP). Preliminary studies suggested that an OD at 600 nm (OD_{600}) of 0.15 ($\sim 10^7$ CFU/ml) facilitated enumeration of adherent *S. epidermidis* cells (see Fig. S1 in the supplemental material). Since enhanced polysaccharide intercellular adhesin (PIA) production is a hallmark of strain 1457 (40), the function of PIA in skin adhesion was assessed using the 1457 and 1457 Δ *ica* strains. These experiments documented that binding of both 1457 and 1457 Δ *ica* strains to the corneocyte-adhered discs was similar, as assessed by confocal microscopy (Fig. 1A and B). Thus, this finding suggests that *S. epidermidis* skin adhesion is independent of PIA and is consistent with the hypothesis that the primary bacterial attachment on the skin is a protein-dependent mechanism.

Sortase mediates the covalent binding of cell surface proteins containing an LPXTG motif to peptidoglycan (41). Indeed, inactivation of *srtA* reduces the localization of cell wall-anchored (CWA) proteins to the cell surface of *S. epidermidis* (32). To investigate the involvement of LPXTG-anchored surface protein adhesins in binding to the skin, a 1457 Δ *srtA* mutant was constructed and investigated for its corneocyte binding efficiency. Both the 1457 Δ *srtA* and 1457 Δ *ica* Δ *srtA* mutants displayed negligible binding to corneocytes (Fig. 1A and B), suggesting the involvement of a CWA protein in the skin adhesion phenotype. *S. epidermidis* expresses 11 proteins containing an LPXTG motif (31), of which Aap and SdrF have been previously shown to possess adhesive properties and have been implicated in facilitation of *S. epidermidis* colonization of skin (38, 39). Similarly to our findings with the sortase mutant, corneocyte discs incubated with Aap-negative *S. epidermidis* 1457 Δ *aap* and 1457 Δ *ica* Δ *aap* mutants showed negligible adherence to corneocytes, in contrast to the Aap-positive 1457 and 1457 Δ *ica* mutant strains (Fig. 1A and B), suggesting that the CWA protein Aap mediates bacterium-host interaction.

To test the function of SdrF in aiding Aap-dependent binding of 1457 to corneocytes, an *sdrF* allelic replacement mutant was constructed in the 1457 Δ *ica* mutant




FIG 2 Relative blocking of 1457/pCM29 using anti-AapA or anti-AapB antisera. (A) Anti-AapA antiserum blocked adherence, whereas anti-AapB antiserum did not. Anti-polysaccharide intercellular adhesin (PIA) antibody was used as a negative control. (B) Dose-dependent decrease of adherent bacteria with increasing concentration of anti-AapA antiserum. (C) No significant decrease in adherence was observed with increasing concentration of anti-AapB antiserum. The number of adherent 1457/pCM29 bacteria preincubated with the indicated dilutions (concentrations) of anti-AapA or anti-AapB antisera was normalized to the mean number of adherent 1457/pCM29 bacteria preincubated with PBS only (considered 100). Comparisons were performed by two-tailed unpaired Student's *t* test with 95% confidence intervals. ***, $P < 0.0001$.

background. The corneocyte binding assay revealed that adhesion of the 1457 Δ *ica* Δ *sdrF* mutant was similar to that of the 1457 Δ *ica* mutant (Fig. 1A and B), implying that in our assay, SdrF does not function to facilitate adherence to corneocytes. Furthermore, the finding that the 1457 Δ *ica* Δ *aap* Δ *sdrF* mutant phenocopied the 1457 Δ *ica* Δ *aap* mutant rather than the 1457 Δ *ica* Δ *sdrF* mutant (Fig. 1A and B) strongly supports the importance of Aap in *S. epidermidis* skin colonization, irrespective of the presence of other CWA adhesins. A defective adherence phenotype of the *aap* mutation also diminishes the likelihood of two or more CWA proteins contributing collectively to the adhesive properties in this strain.

Identification of the Aap domain that mediates binding of *S. epidermidis* to corneocytes. Aap consists of structurally distinct domains (33). The N-terminal A domain of Aap, as well as its *S. aureus* orthologue SasG, have been previously implicated in promoting adhesion to mammalian cells and artificial surfaces (33, 38, 42). Therefore, we hypothesized that the Aap-mediated adherence of strain 1457 to corneocytes observed in Fig. 1 is facilitated by the A domain. To test this hypothesis, a bacterial blocking assay was performed using antiserum raised against the A or B domain of Aap (23). As shown in Fig. 2A, anti-AapA antiserum blocked adherence of 1457 to corneocytes, whereas anti-AapB antiserum did not, suggesting that Aap-mediated adherence of *S. epidermidis* 1457 to corneocytes from the skin primarily involves the A domain. A dose-dependent decrease of adherent bacteria was also observed with increasing concentration of anti-AapA antiserum (Fig. 2B), confirming the function of the Aap A domain in the facilitation of 1457 binding to corneocytes. In contrast, increasing the concentration of anti-AapB antiserum had no effect on adherence to corneocytes (Fig. 2C). Last, antibody raised against PIA (a noncontributing factor in bacterium-skin adherence) was used as a negative control and had no effect on the binding of bacteria (Fig. 2A). Therefore, the 1457 Δ *ica* strain was subsequently used as the wild-type strain background for further studies.

The A domain is composed of a conserved 222-amino-acid globular subdomain that is predicted by bioinformatic analysis to be an L-type lectin-like domain. This lectin-like subdomain is positioned C-terminally to a strain-dependent, variable number of imperfect 16-amino-acid repeat regions (33). However, the particular subdomain that facilitates binding to corneocytes is yet to be identified. To further determine the contribution of the two subdomains, the ability of recombinantly expressed and purified rA_{repeat} and rA_{lectin} subdomain proteins to block adhesion was tested and compared to that of the complete $rA_{\text{rep+lec}}$ domain (Fig. 3A to C). These data demonstrate that the rA_{lectin} subdomain blocked the binding of 1457 to corneocytes in a concentration-dependent




FIG 3 Relative blocking of *S. epidermidis* by recombinant Aap A subdomains. Effect of rAap A subdomains (A repeat and/or lectin) on *S. epidermidis* binding to corneocytes. (A) The $rA_{\text{rep+lec}}$ domain and (B) the rA_{lectin} subdomain block the binding of 1457 $\Delta ica/pCM29$ to corneocytes. In contrast, (C) the rA_{repeat} subdomain was unable to block adherence. (D) Normalization of the blocking with recombinant Aap A domain and its subdomain proteins. The number of adherent 1457 $\Delta ica/pCM29$ bacteria after blocking the corneocytes with the indicated concentrations of the above-mentioned recombinant proteins was normalized to the mean number of 1457 $\Delta ica/pCM29$ bacteria adherent to corneocytes blocked with PBS only (considered 100). Comparisons were performed by two-tailed unpaired Student's *t* test with 95% confidence intervals. *, $P < 0.05$; ***, $P < 0.0001$.

manner, up to a maximum of 60% at 10 μM , similarly to the $rA_{\text{rep+lec}}$ domain (Fig. 3D). In contrast, the rA_{repeat} subdomain was unable to block adherence. These results suggest that the L-type lectin-like subdomain is the key subdomain that contributes to the Aap A domain-mediated bacterium-host attachment.

Binding of 1457 Δica isogenic mutants expressing truncated variants of Aap to corneocytes. Isogenic mutants expressing truncated variants of Aap were generated to confirm the significance of the individual domains of Aap in adherence to corneocytes. Constructs expressing different combinations of the A and B domains were inserted via allelic replacement into the *aap::tetM* allele of the 1457 *ica::dhfr aap::tetM* strain, thus replacing *aap::tetM* with functional *aap*-expressing specific domains. All constructs contained the native *aap* promoter and included the N-terminal signal sequence for extracellular export of the translated protein. The proline/glycine-rich region (PGR) domain, which has been shown to form an extended stalk to resist compaction (43), was added, in addition to the C-terminal LPDTG sortase recognition motif for anchoring the exported protein to the cell wall. The generated knock-in mutants are shown in Fig. 4; pCM29 expressing GFP was transduced into each constructed mutant. To minimize proteolytic cleavage of Aap, the above mutants were grown in tryptic soy broth (TSB) containing the protease inhibitor α_2 -macroglobulin.

To confirm that the constructed knock-in mutants were able to express the appropriate Aap domains on the cell wall, Western blot analysis was performed using anti-AapA and anti-AapB antibodies. First, to determine if the polyclonal anti-AapA antibody could recognize the A_{repeat} and A_{lectin} subdomains individually, a Western blot analysis was performed using purified $rA_{\text{rep+lec}}$ domain and rA_{repeat} and rA_{lectin} subdomains. Although anti-AapA antibody could readily detect the $rA_{\text{rep+lec}}$ domain, the rA_{repeat} subdomain was not detected, and the rA_{lectin} subdomain was weakly detected (Fig. 5A and B). Therefore, we were unable to confirm if the 1457 $\Delta ica aap::A\text{-rep}$ strain expressed the A repeat domain, due to the lack of antibody recognition when Western




FIG 4 Construction of mutants expressing specific domains of Aap. Allelic replacement vectors were constructed to delete specific regions of Aap. Note that intact Aap was reconstructed via insertion of the A-repeat domain into the *1457 icaADBC::dhfr aap::A-lec+B* construct.

blot analysis was performed on its cell wall proteins using anti-AapA antibody (data not shown). Furthermore, we were unable to detect expression of the Aap A-lectin domain from the isolated cell wall proteins of the *1457 Δica aap::A-lec* strain (data not shown). However, using anti-AapA antibody, we were able to detect the Aap A domain from the *1457 Δica aap::A-(rep+lec)* strain (Fig. 5C). Last, cell wall proteins were isolated from the isogenic mutants expressing truncated Aap containing the B domain, and a Western blot analysis was performed using anti-AapB antibody (Fig. 5D). We found that anti-AapB antibody readily detected Aap from the *1457 Δica* and *1457 Δica aap::A-repeat+B* strains. However, Aap was weakly detected in the *1457 Δica aap::B* and *1457 Δica aap::A-lec+B* strains. Interestingly, genetic insertion of the A repeat sequence of *aap* into the *1457 Δica aap::A-lec+B* strain, generating the *1457 Δica aap::A-(rep+lec)+B* strain, restored expression of Aap to the levels observed in the *1457 Δica* and *1457 Δica aap::A-repeat+B* strains. These data may suggest that the A domain, and the A repeat region in particular, may be required for stability of Aap. Importantly, it is well known that Aap does not migrate according to size in SDS-polyacrylamide gels, presumably due to the PGR repeats (43). Interestingly, the ~180-kDa band detected in the *1457 Δica aap::B* strain was slightly larger in size than that detected in the *1457 Δica aap::A-lec+B* strain, which was not predicted (Fig. 5D). Additionally, it is important to note that the presence of the Aap A repeat subdomain also resulted in aberrant migration of the $rA_{rep+lec}$ domain and rA_{repeat} subdomain during SDS-PAGE, during which both migrated to a larger size than predicted (Fig. 5A). Accordingly, the major band detected near 300 kDa in the *1457 Δica* and *1457 Δica aap::A-(rep+lec)+B* strains was slightly larger in size than those in the *1457 Δica aap::A-repeat+B* strain




FIG 5 Use of anti-AapA and anti-AapB to assess expression of Aap in truncated variants. (A) The recombinant $A_{\text{rep+lec}}$ domain (upper band) (lane 1), the rA_{repeat} subdomain (lane 2), and the rA_{lectin} subdomain (lane 3) were electrophoresed through a 10% SDS-PAGE gel and stained with Coomassie blue. Two bands were visible for both the $rA_{\text{rep+lec}}$ domain and the rA_{repeat} subdomain due to the included metalloprotease cleavage site, which is present within the A domain at Leu 335, between the A-repeat and the A-lectin subdomains. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis of the upper and lower bands of the $rA_{\text{rep+lec}}$ domain indicated that the lower band protein is truncated at the C terminus, comprising essentially the A-repeat subdomain. Note that the $rA_{\text{rep+lec}}$ domain and the rA_{repeat} subdomain had aberrant migration. The predicted molecular weights of the $rA_{\text{rep+lec}}$ domain, the rA_{repeat} subdomain, and the rA_{lectin} subdomain are 57 kDa, 32 kDa, and 25 kDa. (B) A Western blot analysis was performed using anti-AapA antibody to detect recombinant proteins. Note the lack of detection of the rA_{repeat} subdomain in lane 2 and the lower band in lane 1. (C) Cell wall proteins were isolated from the 1457 Δica , 1457 $\Delta\text{ica} \Delta\text{aap}$, 1457 $\Delta\text{ica} \text{aap}::\text{B}$, and 1457 $\Delta\text{ica} \text{aap}::\text{A}-(\text{rep}+\text{lec})$ strains and electrophoresed through a 7% SDS-PAGE gel. Aap expression in each mutant was subsequently detected using anti-AapA antibody via Western blot analysis. (D) Cell wall proteins were isolated from the 1457 Δica , 1457 $\Delta\text{ica} \Delta\text{aap}$, 1457 $\Delta\text{ica} \text{aap}::\text{B}$, 1457 $\Delta\text{ica} \text{aap}::\text{A-rep}+\text{B}$, 1457 $\Delta\text{ica} \text{aap}::\text{A-lec}+\text{B}$, and 1457 $\Delta\text{ica} \text{aap}::\text{A}-(\text{rep}+\text{lec})+\text{B}$ strains and electrophoresed through a 7% SDS-PAGE gel. Aap expression in each mutant was subsequently detected using anti-AapB antibody via Western blot analysis.

(Fig. 5D). However, the difference in size between the major bands of the 1457 $\Delta\text{ica} \text{aap}::\text{A-rep}+\text{B}$ and 1457 $\Delta\text{ica} \text{aap}::\text{A-lec}+\text{B}$ strains was much greater than predicted (Fig. 5D).

Our blocking data suggested that the A domain, and, in particular, the lectin subdomain, was required to mediate adherence to corneocytes. To further confirm the contribution of the A repeat region and the A lectin subdomain, the corneocyte binding assay was performed with the 1457 Δica strain expressing only certain domains of Aap (Fig. 6). We found that even though the expression of Aap in the 1457 $\Delta\text{ica} \text{aap}::\text{A-rep}+\text{B}$ strain was comparable to that in the 1457 Δica strain (Fig. 5D), no corneocyte adherence was detected in the 1457 $\Delta\text{ica} \text{aap}::\text{A-rep}+\text{B}$ strain (Fig. 6). In contrast, even though the expression of Aap in the 1457 $\Delta\text{ica} \text{aap}::\text{A-lec}+\text{B}$ strain was reduced in comparison to that in the 1457 $\Delta\text{ica} \text{aap}::\text{A-rep}+\text{B}$ strain (Fig. 5D), significant corneocyte adherence was observed for the 1457 $\Delta\text{ica} \text{aap}::\text{A-lec}+\text{B}$ strain (Fig. 6). These data confirm that the lectin subunit of the A domain, and not the A repeat region, is responsible for corneocyte adherence. The corneocyte binding ability of the 1457 $\Delta\text{ica} \text{aap}::\text{A}-(\text{rep}+\text{lec})+\text{B}$ strain, expressing the B domain with the full-length A domain, was restored to the level of the 1457 and 1457 Δica strains (Fig. 6). These results suggest that the A-repeat domain may function to properly position the lectin subdomain for appropriate interaction with the corneocyte ligand in addition to the aforementioned possibility of conferring expression stability, as seen in Fig. 5D. Furthermore, negligible corneocyte adherence was detected using the 1457 $\Delta\text{ica} \text{aap}::\text{A}-(\text{rep}+\text{lec})$ strain, suggesting that the B domain may function to extend the A domain away from the cell wall to bind a ligand (Fig. 6). Additionally, no corneocyte adherence was observed for the 1457 $\Delta\text{ica} \text{aap}::\text{A-lec}$, 1457 $\Delta\text{ica} \text{aap}::\text{A-rep}$, and 1457 $\Delta\text{ica} \text{aap}::\text{B}$ strains (Fig. 6).




FIG 6 Corneocyte binding of 1457 Δ *ica* isogenic mutants expressing truncated variants of Aap. Mean number (with SEM) of adherent 1457 Δ *ica* truncated *aap* variants expressing GFP (per 89.8- μ m \times 89.8- μ m sections). Comparisons between individual mutants were performed by two-tailed unpaired Student's *t* test with 95% confidence intervals. ***, $P < 0.0001$.

Glycan distribution on the surface of corneocytes. L-type lectin domains are protein domains with homology to the leguminous plant lectins which specifically bind carbohydrates. Therefore, we hypothesized that the predicted lectin domain of Aap has affinity for glycan moieties in the stratum corneum (SC) corneocytes that serve as binding partners. Eukaryotic cells have a rich and diverse surface glycan coat that constitutes the cell interface with the environment (44). However, the glycome (the sum of its diverse glycan structures) on every human tissue is distinct and is defined by expression levels of the enzymes responsible for glycan biosynthesis (45). The presence and distribution of various surface glycan moieties on corneocytes were thus detected utilizing a lectin-labeling technique. As noted in Fig. S2A and B in the supplemental material, commercially available rhodamine-labeled lectins that bind specific configurations of sugar molecules were able to detect different glycan moieties present on the surface of corneocytes from the upper layers of the stratum corneum in various distribution patterns. The results indicated that glycans persist on the surfaces of corneocytes taken from the forearm, and the labeling patterns suggested the presence of different sugar moieties in specific distribution patterns.

***S. epidermidis* binding of corneocytes after elimination of specific glycan structures by glycosidases.** In human skin, *N*-linked glycosylation is the most common type of posttranslational modification on Asn-X-Ser/Thr motifs of epidermal proteins (46). A second major glycosylation found on the surface of keratinocytes is the covalent *O*-linkage to Ser/Thr residues of proteins (47). We reasoned that enzymatic treatment of corneocyte surfaces prior to addition of *S. epidermidis* with the endoglycosidases PNGase F (removes *N*-linked oligosaccharides from glycoproteins, cleaving between the innermost GlcNAc and asparagine residue) and/or *O*-glycosidase (removes core 1 and core 3 *O*-linked disaccharides from glycoproteins) would result in reduced adherence of the 1457 Δ *ica* strain to corneocytes. Indeed, enzymatic treatment with both PNGase and *O*-Glycosidase reduced adherence of the 1457 Δ *ica* strain by approximately 50%, suggesting that both of these glycan linkages expressed in the host SC are important in *S. epidermidis* adherence (Fig. 7A and B).

Based on these results, corneocytes were pretreated with specific exoglycosidases that catalyze hydrolysis of particular terminal sugar residues from glycoforms to assess the involvement of 5-*N*-acetylneuraminic acid (sialic acid), fucose, galactose, *N*-acetylglucosamine,




FIG 7 *S. epidermidis* corneocyte adherence following glycosidase treatment. Corneocytes were treated with specific glycosidases (A to G), and the number of adherent $1457\Delta_{ica}/pCM29$ bacteria after deglycosylation was normalized to the mean number of $1457\Delta_{ica}/pCM29$ bacteria adherent to corneocytes preincubated with buffer only (considered 100). Comparisons were performed by two-tailed unpaired Student's *t* test with 95% confidence intervals. ***, $P < 0.0001$.

and mannose terminal sugars in binding *S. epidermidis*. Significant reduction in the $1457\Delta_{ica}$ strain binding was observed in $\alpha 2-3,6,8$ neuraminidase-, $\alpha 1-3,4$ fucosidase-, and $\beta 1-4$ galactosidase S-pretreated corneocytes (Fig. 7C to E), confirming the importance of 5-*N*-acetylneuraminic acid, fucose, and galactose in contributing to ligand configuration,

either individually or together. In contrast, pretreatment of corneocytes with β -*N*-acetylglucosaminidase S and α 1-2,3 mannosidase, to remove *N*-acetylglucosamine and mannose residues, respectively, did not result in any reduction in binding of the 1457 Δ *ica* strain to corneocytes (Fig. 7F and G), suggesting that these residues either do not function in forming the ligand structure or their removal does not prevent the bacterial receptor from binding the ligand in the corneocytes. To confirm the activity of specific glycosidase treatment, corneocytes were stained with rhodamine-labeled lectins following enzymatic treatment and thus documenting reduced staining (see Fig. S3 in the supplemental material).

Genome analysis of predominant coagulase-negative staphylococci. The presence of protein sequences homologous to that of *S. epidermidis* 1457 Aap (GenBank accession no. [ARG65518.1](#)) in common staphylococcal skin commensals was investigated by bioinformatics analyses. The protein was considered present when a BLAST match with an alignment score of ≥ 200 was recorded, as shown in Table S3 in the supplemental material. Sequence similarity of the lectin domain of these homologous proteins was also compared to the 1457 Aap lectin domain to ensure elimination of Aap-like protein sequences having only G5-E domains and no lectin domain. As shown in Fig. 8A, *S. hominis* and *S. haemolyticus* strains have homologous Aap sequences with high percent identities to *S. epidermidis* 1457 Aap, as well as to the Aap lectin domain. Aap homologues, including the lectin domain, were also found in strains of *Staphylococcus saprophyticus* and *S. capitis*. On the other hand, *Staphylococcus simulans* has a protein in most strains annotated as “E domain-containing protein,” with 27 to 47% homology to 1457 Aap. However, this predicted protein consists of only G5 domains. The lectin domain is not present in any of the Aap homologous protein sequences, nor as a part of any other proteins in *S. simulans*. Likewise, two strains of *Staphylococcus warneri* were also found to encode an Aap-like protein with only G5 domains and no lectin domain. Therefore, corneocyte binding assays were performed using crystal violet staining and light microscopy (Fig. 8B). These assays documented that *S. hominis*, *S. haemolyticus*, and *S. saprophyticus* bound to the corneocytes similarly to the 1457 Δ *ica* strain, whereas *S. capitis*, *S. simulans*, and *S. warneri* exhibited either decreased (*S. capitis* and *S. simulans*) or peripheral adherence (*S. warneri*) (Fig. 8B). Overall, these data suggest that the Aap orthologues may function to provide the basis for staphylococcal colonization of the skin, with the L-type lectin domain operating as receptors for specific ligands on the surface of corneocytes.

Corneocyte binding of *S. aureus*. Despite possessing the Aap orthologue SasG, *S. aureus* is not a normal component of the normal human skin microbiota. Indeed, many *S. aureus* strains, including JE2, have premature stop codons within *sasG*, which presumably result in a nonfunctional protein. Therefore, we chose to work with *S. aureus* MW2, which has been previously shown to express a functional SasG (48). As shown in Fig. 9, *S. aureus* MW2 and MW2 Δ *sasG* strains displayed negligible adherence to corneocytes. However, it has been previously demonstrated that the transcription of *sasG*, as well as that of seven other cell wall-associated proteins, is repressed by the global regulator MgrA, which in turn is regulated by the ArlRS two-component regulatory system (48). Thus, the contribution of MgrA was assessed in the corneocyte adherence assay. Indeed, the binding of MW2 increased significantly in the MW2 Δ *mgrA* mutant. This increase in adherence was confirmed to be SasG dependent, as the phenotype of the MW2 Δ *mgrA* Δ *sasG* mutant phenocopied that of MW2, suggesting that derepression of SasG in the absence of MgrA can significantly increase the binding of *S. aureus* to corneocytes. Thus, these data confirm that when SasG is expressed, it is able to mediate significant binding of *S. aureus* to corneocytes, similarly to *S. epidermidis*, reiterating the importance of Aap and its orthologues in the adherence of staphylococci to healthy skin.

DISCUSSION

There is emerging evidence that *S. epidermidis* and other commensal staphylococci ubiquitously present on cutaneous surfaces inhibit the colonization of harmful pathogenic microorganisms (9–14, 49). Although pathogen inhibition clearly involves production of




FIG 8 Coagulase-negative staphylococci adherence to corneocytes. (A) Representative image of genome analysis of predominant commensal coagulase-negative staphylococcal species. (B) Corneocyte binding assay visualized after crystal violet staining under light microscopy with $\times 40$ magnification objective. The *S. epidermidis* 1457 Δica strain was used as a positive control, whereas 1457 $\Delta ica \Delta aap$ and the adhesion-negative *Staphylococcus carnosus* served as negative controls.

inhibitory compounds by CoNS and other commensals, we surmise that adherence to corneocytes, and potentially intercellular aggregation, is a prerequisite for secretion of these compounds. Furthermore, *S. epidermidis* and other commensals may have evolved to adhere to specific ligands, thus successfully outcompeting *S. aureus*. Therefore, we propose that determining how *S. epidermidis* adheres to corneocytes is a missing component of understanding the pathogenesis of *S. aureus* skin and soft tissue infections. Indeed, understanding these interactions may reveal how *S. aureus* evolved to counteract inhibition by *S. epidermidis* and other CoNS.

This study demonstrated that Aap is a critical adhesin that mediates adherence of *S. epidermidis* 1457 to corneocytes. Our experiments confirmed that the Aap-mediated




FIG 9 Derepression of SasG in the MW2 $\Delta mgrA$ strain significantly increases adherence of *S. aureus* to corneocytes. (A) Corneocyte binding assay performed with *S. aureus* MW2/pCM29 and mutants, visualized by confocal microscopy at 40×0.6 magnification and (B) 63×1.5 magnification. (C) Mean number (with SEM) of MW2/pCM29 and mutants adhered to corneocytes (per $89.8\text{-}\mu\text{m} \times 89.8\text{-}\mu\text{m}$ sections) after corneocyte binding assay. Comparisons between individual mutants were performed by two-tailed unpaired Student's *t* test with 95% confidence intervals. ***, $P < 0.0001$.

adherence of 1457 to corneocytes occurs primarily via interactions of the A domain with corneocytes. The conserved globular lectin-like subdomain was found to mediate adherence to surface ligands in the corneocytes and confer the A domain with optimum binding capacity. Inhibition of bacterial adherence using anti-Aap antiserum specific for either the A or B domains or the use of recombinant domain proteins provided results documenting the importance of the complete A domain and the lectin subdomain in the binding process. However, failure to completely prevent bacterial adherence even after blocking with a high concentration of the $rA_{\text{rep+lec}}$ domain ($10\ \mu\text{M}$) (Fig. 3C), in contrast to the nearly complete blocking of adherence via anti-AapA domain antiserum (Fig. 2A), suggested loss of structural integrity or reduced binding affinity in the recombinant soluble form of the $A_{\text{rep+lec}}$ domain. Interestingly, 50% blocking required $2.48\ \mu\text{M}$ $rA_{\text{rep+lec}}$ domain compared to $7.54\ \mu\text{M}$ rA_{lectin} domain. Therefore, a lower concentration of the $rA_{\text{rep+lec}}$ domain than the rA_{lectin} domain is required to bind half the available ligands present on corneocytes, indicating that the $rA_{\text{rep+lec}}$ domain has higher blocking efficiency than the rA_{lectin} domain. Therefore, we speculate that the complete $rA_{\text{rep+lec}}$ domain might possess a higher affinity for the ligand on the corneocyte than rA_{lectin} domain alone and hypothesize that the 16-amino-acid repeat region present N-terminally to the lectin domain provides conformational precision for the lectin domain to bind the ligand in the stratum corneum of the skin. Alternatively, since the Aap lectin domain is predicted to possess homodimer and homotetramer interaction sites for oligomeric interactions (predicted by the NCBI Conserved Domains Database), multiple copies of Aap lectin domains expressed together in *S. epidermidis* might show multivalent interactions with corneocyte ligands with higher binding avidity than that of the monovalent recombinant forms. Corneocyte binding assays performed using isogenic mutants expressing truncated variants of Aap confirmed that while the lectin subdomain binds to corneocytes, the N-terminal A-repeat region also functions to provide the lectin domain with the maximum binding ability, and the B domain functions, presumably, to extend the A domain, facilitating interaction with the corneocyte ligand.

Many studies have suggested that infection or colonization by bacteria is generally initiated by the specific recognition of host epithelial surfaces by adhesins and lectins. Glycans are present on all cell types and have specific biological functions in cell-cell recognition and cell-matrix interactions within the host (50). Pathogens have evolved to exploit these cell surface glycans by recognizing specific sequences of glycans as targets to bind host cells. Adhesins expressed on the surface of these microorganisms are often equipped with lectin domains that mediate binding to such glycans presented on proteins or lipids on the host surface (50). We hypothesize that the lectin-like domain of Aap binds glycans present on the surface of the corneocytes. The use of glycosidases suggested that the terminal glycans expressed in the host stratum

corneum serve as binding partners for the Aap-mediated colonization of *S. epidermidis* on the corneocyte surface. Indeed, antibodies against the highly expressed corneocyte proteins loricrin and cytokeratin-10 had no effect on *S. epidermidis* adherence (see Fig. S4 in the supplemental material). Given the terminal location of the negatively charged sialic acid in most human glycoforms and their widespread distribution, sialic acids are often the targets for binding by a large number of pathogenic organisms and their toxins (51). Hence, we hypothesize that Neu5Ac might present an important structure for *S. epidermidis* ligand in corneocytes. Galactose, GlcNAc, and fucose also form terminal “decorating” sugars, and thus we speculate the involvement of these sugars in *S. epidermidis* adherence. It should also be noted that the complete loss of *S. epidermidis* adherence to corneocytes was not observed following glycosidase treatment (Fig. 7). These results may suggest an incomplete removal of glycan moieties by the endoglycosidases, probably due to the difficulty in accessing the interior target in the presence of lipid-rich layers on the corneocyte sheets. Alternatively, it might suggest that glycolipids, in addition to glycoproteins, have a function in *S. epidermidis* adherence. Taken together, the results generated by this study demonstrate that the adherence of *S. epidermidis* to corneocytes is dependent on terminal sugar residues, with sialic acid, fucose, and galactose being the most promising binding ligands (Fig. 7).

Aap is a multifunctional protein that contributes to both primary attachment and subsequent biofilm accumulation (32, 33, 35). These well-defined functions are mediated by its structurally distinct A and B domains (29, 36, 37). Studies show that expression of full-length Aap mediates attachment of *S. epidermidis* to uncoated abiotic surfaces, presumably through hydrophobic interactions via the A domain (32, 33). Additionally, Schaeffer et al. found that *S. epidermidis* adherence to a rat jugular catheter was dependent upon Aap (33). It is unclear, however, if the same glycan expressed on corneocytes is also coated on catheters or whether Aap binds multiple glycan ligands. Additionally, Aap is subjected to proteolytic processing by the SepA metalloprotease (or by host-derived proteases), which results in distinct isoforms of the expressed protein (33–35). Based on Western blot analysis (34), we predict that about half of the cell wall-associated Aap molecules are processed by SepA. Thereafter, processed Aap can participate in Zn²⁺-dependent intercellular adhesion via the B domains to facilitate cellular aggregation and/or biofilm accumulation in *S. epidermidis*. Moreover, SepA-mediated proteolysis of Aap within the A domain (at Leu 335) and at the junction between the A and B domains (at Leu 601) is under the regulation of the global transcriptional regulator, SarA, thus allowing *S. epidermidis* to fine-tune its biofilm-inducing properties in response to environmental cues (34). However, it is unclear if Aap processing via SepA has a specific function with regard to *S. epidermidis* adherence to corneocytes. We propose that, following A lectin-mediated adherence to the glycan, processed Aap facilitates additional cellular aggregation allowing for increased colonization of the skin surface (Fig. 10). Indeed, Gonzalez and colleagues recently found via scanning electron microscopy that bacteria colonizing skin were observed as aggregates of cells, suggesting that subsequent B domain-mediated aggregation may be important for skin surface colonization (52).

Commensal staphylococcal species possessing homologous Aap adhesins with a functional lectin-like domain may also function to bind corneocyte glycan ligands, similarly to *S. epidermidis*. We were able to confirm this in *S. aureus* MW2 strain expressing SasG, an orthologue of Aap. Though L-type lectins exhibit both sequence and structural similarity to one another, their carbohydrate binding specificities differ widely depending on the residues of the adjoining sequence of the carbohydrate binding site. Thus, it is possible that each CoNS species exhibits specificity for distinct sugar residues or moieties, which might explain the observed binding pattern differences between different strains. Alternatively, SasG and Aap (or other staphylococcal Aap orthologues) may bind similar glycan moieties, and competition for these binding sites may exist. This may suggest that *S. aureus* is selected to repress SasG via MgrA to avoid competition with *S. epidermidis* and/or other coagulase-negative staphylococcal species. Indeed, many strain backgrounds, including USA300, the most prominent *S. aureus* lineage causing infections in the United States, encode a truncated and




FIG 10 *S. epidermidis* adherence to corneocytes. A hypothetical model of *S. epidermidis* binding to glycans linked to proteins or lipids that are expressed on the surface of corneocytes. It is proposed that *S. epidermidis* expressing the full-length Aap on its cell wall adheres to corneocytes from the uppermost layers of the skin epidermis via the A domain. Aap A domain-mediated binding is dependent upon the lectin subdomain but requires the A-repeat domain and the B domain for maximum ligand-receptor interaction. Aap may bind to a specific glycan molecule or bind to multiple glycan molecules with different affinities. Furthermore, SepA, which is regulated by SarA, processes Aap, facilitating B domain-mediated interactions and subsequent cellular aggregation on the corneocyte surface.

presumably nonfunctional SasG protein, suggesting that certain populations of *S. aureus* may use alternative strategies to facilitate corneocyte adherence (48, 53).

Conventionally, glycan recognition by proteins is of low affinity compared to protein-protein interactions, which typically have high binding affinities. However, since adhesins and ligands often cluster in the plane of the membrane, the resulting combinatorial avidity can be high (50, 54). It is also possible that *S. epidermidis* has adhesins that promote glycan-independent mechanisms of interaction with the host corneocyte proteins, in a similar manner as SdrF binding to cytokeratins (39). Nevertheless, glycan-dependent binding mechanisms often function to play a role in the first step of adhesion, prior to invasion during infections. It can also be advantageous in harsh environmental conditions where opportunities for contact and adherence may be transient and difficult (53, 54).

In conclusion, *S. aureus* is the most significant cause worldwide of skin and skin structure infections. However, *S. aureus* is infrequently isolated from the skin from healthy subjects. This suggests that *S. epidermidis* and other bacteria colonizing the skin are highly effective at inhibiting colonization of this pathogen. We found that *S. epidermidis* binds to healthy corneocytes using Aap and that other coagulase negative staphylococci also contain an Aap orthologue, suggesting a potential common mechanism for corneocyte adherence. These data may suggest that *S. epidermidis* has the ability to outcompete *S. aureus*, potentially via adherence to carbohydrate molecules decorating corneocytes. Further studies will focus on competition between these two species, determine whether SasG and Aap bind similar ligands and, potentially, determine if *S. aureus* uses other adhesins to bind healthy or diseased skin.

MATERIALS AND METHODS

Bacterial strains and medium. Bacterial strains and plasmids used in these studies are described in Table S1 in the supplemental material. *S. epidermidis* strains were grown in tryptic soy broth (TSB) or agar (Difco). *Escherichia coli* DH5 α , used for cloning purposes, and *Escherichia coli* BL21(DE3), used for

overexpressing recombinant proteins, was grown in lysogeny broth or agar (LB; Difco). Antibiotics and concentrations for cloning and selection purposes were as follows: ampicillin (50 $\mu\text{g/ml}$), kanamycin (100 $\mu\text{g/ml}$), tetracycline (5 $\mu\text{g/ml}$), erythromycin (10 $\mu\text{g/ml}$), chloramphenicol (10 $\mu\text{g/ml}$), and trimethoprim (10 $\mu\text{g/ml}$). Cultures were grown aerobically (1:10 medium-to-flask ratio, 250 rpm) at 37°C or at 30°C (for temperature-sensitive strains).

Construction of recombinant His₆-tagged fusion proteins. First, a 1,602-bp fragment containing the A domain sequence of *aap* from *S. epidermidis* 1457 (55) was amplified using primers *r-aapAdom F* and *r-aapAdom R*. Similarly, 915 bp of the A-repeat region of *aap* was amplified using the primers *r-aapAdom F* and *r-aapArep R*, and 681 bp of the L-type lectin domain of *aap* was amplified using the primers *r-aapLec F* and *r-aapAdom R*. PCR was carried out using chromosomal DNA from *S. epidermidis* strain 1457 as the template and Q5 high-fidelity DNA polymerase (New England Biolabs [NEB], Ipswich, MA) according to the manufacturer's instructions. The primers used are listed in Table S2 in the supplemental material. The resulting amplicons were cloned into pET28a using the NdeI and XhoI restriction sites, creating plasmids pNF319, pNF326, and pNF318 for N-terminal His₆-tagged rA_{rep+lec} domain, rA_{repeat} subdomain, and rA_{lectin} subdomain, respectively, in chemically competent *E. coli* DH5 α cells. The primers T7Promoter F and T7Terminator R were used for confirming the inserts by PCR. Plasmid DNA was isolated from *E. coli* DH5 α using the Wizard Plus SV Minipreps DNA purification system (Promega, Madison, WI) according to the manufacturer's recommendations. The plasmids were transformed into chemically competent *E. coli* BL21(DE3) cells for overexpression of the recombinant proteins.

Expression and purification of recombinant proteins. For recombinant expression of the A_{rep+lec} domain and subdomains A_{repeat} and A_{lectin}, BL21(DE3)/pNF319, BL21(DE3)/pNF326, and BL21(DE3)/pNF318 were induced using autoinduction medium (adapted from Studier [56]) for 18 h at 37°C under aerobic conditions. Induced cultures were pelleted and resuspended for lysis in 6 ml of lysis buffer containing BugBuster protein extraction reagent (EMD Millipore, Billerica, MA), EDTA-free cOmplete protease inhibitor cocktail (Roche, Mannheim, Germany), and benzonase nuclease (EMD Millipore), for 20 min at room temperature under gentle shaking conditions. Samples were then centrifuged at 4°C and supernatants incubated with 1-ml resins charged with divalent cobalt provided in HisPur cobalt spin columns (Pierce Biotechnology, Rockford, IL) overnight on an end-over-end mixer at 4°C for affinity purification of the recombinant proteins. Columns were then washed and eluted following the manufacturer's instructions. Affinity-purified proteins were concentrated at 20°C using a Vivaspin 10,000-molecular weight cut-off (MWCO) column (Sartorius AG; Göttingen, Germany) and stored in phosphate-buffered saline (PBS) with 30% glycerol at -20°C. SDS-PAGE and subsequent Coomassie staining tested the integrity of the respective protein preparations.

Construction of *srtA* and *sdrF* allelic replacement knockout mutants in strain 1457. To construct the *sdrF* allelic replacement plasmid, PCR was performed using chromosomal DNA from *S. epidermidis* 1457 as the template and Phusion high-fidelity DNA polymerase (NEB) according to the manufacturer's instructions. The primers used are listed in Table S2. A 1,001-bp fragment, containing the 3' region of *sdrF* and downstream sequence, was amplified using the primers *sdrFDN F* and *sdrFDN R*. The fragment was inserted into the XmaI and SalI sites of the shuttle vector pJB38 (57), creating plasmid pNF360. A 1,001-bp fragment, containing the 5' region of *sdrF* and upstream sequence, was amplified using the primers *sdrFUP F* and *sdrFUP R*. The fragment was inserted into pNF360 between the SacI and XmaI sites, creating pNF361. A 1,260-bp fragment containing the *ermC* cassette was amplified from pROJ6448 (58) with XmaI ends using the primers *ermC-XmaI F* and *ermC-XmaI R*. The fragment was inserted in the XmaI site of pNF361, creating the *sdrF* allelic replacement plasmid pNF362. The inserts were confirmed by restriction analysis and PCR with the primers pJB38seq F and pJB38seq R. Subsequently, pNF362 was electroporated into electrocompetent PS187 cells (59) (0.1-cm cuvette, 100 Ω , 25 μF , and 2.3 kV) (60), followed by transduction into the *S. epidermidis* 1457 *icaADBC::dhfr aap::tetM* strain (33) with bacteriophage Φ 187 (59), using a previously described protocol (61). Allelic exchange was performed thereafter to generate single and double recombinants, as previously described (62). Single recombinants were selected for resistance to trimethoprim, tetracycline, erythromycin, and chloramphenicol, while the allelic replacement mutant generated from double recombination was selected based on loss of resistance to chloramphenicol alone (plasmid marker). Following allelic replacement, the *sdrF* mutant was backcrossed into the 1457 *icaADBC::dhfr* (63) and 1457 *icaADBC::dhfr aap::tetM* strains using the transducing phage Φ 71 (64), to generate the 1457 *icaADBC::dhfr sdrF::ermC* and 1457 *icaADBC::dhfr aap::tetM sdrF::ermC* mutants, respectively. The allelic replacement mutants were confirmed by PCR with the primers *sdrFseq F* and *sdrFseq R* and pulsed-field gel electrophoresis (PFGE) as previously described (65).

To construct the *srtA* allelic replacement plasmid, PCR was performed using chromosomal DNA from *S. epidermidis* 1457 as the template and *Taq* DNA polymerase. The primers used are listed in Table S2. A 2,074-bp fragment containing the *srtA* gene and its upstream and downstream sequence was amplified with primers *srtAUP F* and *srtADN R* and cloned into pCR2.1 by TA cloning, creating plasmid pNF79. The insert flanked by EcoRI sites was excised from pNF79 and cloned into the EcoRI site of pUC19, creating plasmid pNF82. A 2,383-bp *tetM* cassette was amplified from pNF105 with Clal ends using the primers *tetM-Clal F* and *tetM-Clal R* and inserted into the Clal site in the middle of the *srtA* gene of pNF82, creating plasmid pNF107. Finally, pROJ6448, containing a temperature-sensitive origin of replication and conferring erythromycin resistance, was linearized with PstI and ligated into the PstI site of pNF107, generating the *srtA* allelic replacement plasmid pNF112. All of the above-described cloning were done in *E. coli* DH5 α cells. Subsequently, pNF112 was electroporated into electrocompetent PS187 cells (0.1-cm cuvette, 100 Ω , 25 μF , and 2.3 kV) and then transduced into *S. epidermidis* 1457 using bacteriophage Φ 187. Allelic exchange was performed thereafter to generate single and double recombinants. Single recombinants were selected for resistance to tetracycline and erythromycin. The allelic replacement mutant

generated from double recombination was able to grow on tryptic soy agar with tetracycline (TSA+Tet) but not on TSA+Erm. Following allelic replacement, the *srtA* mutant was backcrossed into the 1457 and 1457 *icaADBC::dhfr* strains, using the transducing phage Φ 71, to generate the 1457 *srtA::tetM* and 1457 *icaADBC::dhfr srtA::tetM* mutants, respectively. The allelic replacement mutants were confirmed by PCR and PFGE.

Construction of *aap* allelic replacement knock-in mutants expressing truncated variants of Aap in the 1457 Δ ica strain. Isogenic mutants expressing truncated variants of Aap from i to vi were generated by insertion of plasmid constructs containing specific combinations of *aap* domains (markerless) into the 1457 *icaADBC::dhfr aap::tetM* construct by allelic replacement of Δ *aap::tetM*. All of the allelic exchange constructs contained the upstream and downstream region of *aap* for upstream and downstream homologous recombination, respectively. Allelic exchange constructs for the following mutants were made as described below. PCR amplifications were carried out using chromosomal DNA from *S. epidermidis* 1457 as the template and one of the following polymerases: Q5 high-fidelity DNA polymerase (NEB), PfuII long-range DNA polymerase (Monserate Biotechnology Group, San Diego, CA), or Phusion high-fidelity DNA polymerase (NEB). The primers used are listed in Table S2.

(i) The 1457 Δ ica *aap::A-(rep+lec)* construct. For the upstream insert, a 2,609-bp fragment comprising the *aap* upstream region (UP), the signal sequence (SS), and the complete A-domain sequence of *aap* was amplified with primers *aapUP* F1 and *aapAdom* R. The amplified fragment was inserted in between the EcoRI and XmaI restriction site of the shuttle vector pJB38, to create pNF344. For the downstream insert, a 1,369-bp fragment comprising the PGR region, the LPDTG Gram-positive anchor domain, and the downstream region (DN) of *aap* was amplified with the primers *aapPGR* F and *aapDN* R. This fragment was inserted into the XmaI and Sall site of pNF344 to generate pNF348 [*aapA-(rep+lec)* allelic exchange vector]. pNF348 was used to create a B domain-lacking 1457 Δ ica *aap::A-(rep+lec)* mutant for expressing a truncated variant of Aap with only the A domain attached to the PGR stalk and the LPDTG Gram-positive anchor.

(ii) The 1457 Δ ica *aap::B* construct. For the upstream insert, a 1,001-bp fragment comprising the *aap* UP and SS of *aap* was amplified with primers *aapUP* F and *aapSS* R. The fragment was cloned into the EcoRI and XmaI site of pJB38 to create pNF334. For the downstream insert, a 3,940-bp fragment containing the B domain, PGR region, and LPDTG Gram-positive anchor domain of *aap*, along with the *aap* DN, was amplified with *aapBdom* F and *aapDN* R. This fragment was cloned into the XmaI and Sall site of pNF334, generating pNF343 (*aapB* allelic exchange vector). pNF343 was used to create an A domain-lacking 1457 Δ ica *aap::B* mutant for expressing a truncated variant of Aap with only the B domain attached to the PGR stalk and LPDTG Gram-positive anchor.

(iii) The 1457 Δ ica *aap::A-rep* construct. For the upstream insert, a 1,916-bp fragment comprising the *aap* UP, the SS, and the A-repeat region of *aap* was amplified with the primers *aapUP* F1 and *aapArep* R. The fragment was cloned into the EcoRI and XmaI site of pJB38 to create pNF346. For the downstream insert, the 1,369-bp [*aap*(PGR+LPDTG)+DN] fragment amplified previously with the primers *aapPGR* F and *aapDN* R, was cloned into the XmaI and Sall site of pNF346 to generate pNF347 (*aapA-rep* allelic exchange vector). pNF347 was used to create the 1457 Δ ica *aap::A-rep* mutant for expressing a truncated variant of Aap with only the A-repeat region attached to the PGR stalk and LPDTG Gram-positive anchor, devoid of the A-lectin subdomain and the B domain.

(iv) The 1457 Δ ica *aap::A-lec* construct. The 1,369-bp insert [*aap*(PGR+LPDTG)+DN] amplified above with primers *aapPGR* F and *aapDN* R, was cloned into the XmaI and Sall site of the previously generated pNF334, creating pNF345. Next, 687 bp of the lectin domain sequence of *aap* was amplified with *aapAlec* F and *aapAdom* R and cloned into the XmaI site of pNF345. The directionality of the *aapA-lectin* insert was checked with *aapAlecOut* and *aapUP* F. The resulting generated construct was named pNF350 (*aapA-lec* allelic exchange vector). pNF350 was used to create the 1457 Δ ica *aap::A-lec* mutant for expressing a truncated variant of Aap with only the A-lectin subdomain attached to the PGR stalk and LPDTG Gram-positive anchor, devoid of the A-repeat region and the B domain.

(v) The 1457 Δ ica *aap::A-rep+B* construct. The 3,940-bp fragment containing [*aap*(B+PGR+LPDTG)+DN], amplified previously with *aapBdom* F and *aapDN* R, was cloned into the XmaI and Sall site of the previously generated pNF346, creating pNF349 (*aapA-rep+B* allelic exchange vector). pNF349 was used to create an A-lectin subdomain-lacking 1457 Δ ica *aap::A-rep+B* mutant for expressing a truncated variant of Aap with the A-repeat region attached to the B domain, PGR stalk, and LPDTG Gram-positive anchor.

(vi) The 1457 Δ ica *aap::A-lec+B* construct. A 4,648-bp fragment comprising the A-lectin subdomain, B domain, PGR region, and LPDTG Gram-positive anchor of *aap*, along with *aap* DN, was amplified with primers *aapAlec* F and *aapDN* R. This fragment was cloned into the XmaI and Sall site of the previously made pNF334, generating pNF342 (*aapA-lec+B* allelic exchange vector). pNF342 was used to create an A-repeat region-lacking 1457 Δ ica *aap::A-lec+B* mutant for expressing a truncated variant of Aap with the A-lectin subdomain attached to the B domain, PGR stalk, and LPDTG Gram-positive anchor.

All of the above allelic exchange plasmids were constructed in *E. coli* DH5 α cells. The inserts were confirmed by restriction analysis and PCR with the primers pJB38seq F and pJB38seq R. These plasmids were electroporated into electrocompetent PS187 cells (0.1-cm cuvette, 100 Ω , 25 μ F, and 2.3 kV) and then transduced into the *S. epidermidis* 1457 *icaADBC::dhfr aap::tetM* mutant using bacteriophage Φ 187. Allelic exchange was performed thereafter to generate single and double recombinants. Single recombinants were selected for resistance to trimethoprim and tetracycline and chloramphenicol, while the knock-in mutants generated from double recombination were selected based on loss of resistance to tetracycline and chloramphenicol. The mutants thus generated (i to vi) were confirmed by PCR with the primers *aapUP*seq F and *aapDN*seq R, PFGE, and immunoblotting with antibodies to Aap.

(vii) The 1457 Δ ica aap::A-(rep+lec)+B construct. pNF344 containing the insert [UP+aap(SS+A-(rep+lec))] was used as the allelic exchange vector for introducing the A-repeat region back into the 1457 Δ ica aap::A-*lec*+B strain for regenerating the wild-type *aap* genetically. For this purpose, pNF344 was electroporated into electrocompetent PS187 and transduced into the 1457 Δ ica aap::A-*lec*+B mutant using bacteriophage Φ 187. Allelic exchange was performed thereafter to generate single recombinants that were resistant to trimethoprim and chloramphenicol, while double recombinants were selected based on loss of chloramphenicol resistance on the plasmid. The knock-in mutants were selected from double recombinants based on PCR confirmation with the primers *aapAlecOut* and *aapUP* F. Mutant construction was also verified by PFGE and immunoblotting with Aap antibodies.

Preparation of cell wall proteins. Fresh TSB (12.5 ml in a 125-ml flask) was inoculated at an OD₆₀₀ of 0.02, and the cultures were grown to the exponential phase at 37°C with shaking at 250 rpm until an OD₆₀₀ of ~0.7 was reached. Cells were collected by centrifugation at 5,000 rpm for 10 min at 4°C, and the pellet was washed three times with 1 ml 1× PBS (Dulbecco's PBS, no calcium, no magnesium). To isolate cell walls, cell pellets were resuspended in 200 μ l lysis buffer (50 mM Tris-HCl [pH 7.5], 20 mM MgCl₂, 30% [wt/vol] raffinose, 1 mM EDTA, 20 U DNase I [Roche], 4 mM phenylmethylsulfonyl fluoride, 1 mM *N*-ethylmaleimide, 25 mM aminocaproic acid, lysostaphin [100 mg/ml; AMBI Products, Lawrence, NV], and lysozyme [100 mg/ml]) and incubated at 37°C with shaking for 30 min. Cell walls were separated from protoplasts by centrifugation at 6,000 \times g for 20 min. The supernatant (cell wall fraction) was removed, and samples were stored at -20°C.

Western blot analysis. The concentration of protein samples was determined using a NanoDrop 2000 spectrophotometer (Thermo Scientific, Waltham, MA) or with bicinchoninic acid (BCA) assay (Pierce Biotechnology). Samples were adjusted for equal protein amount (35 μ g total protein for cell wall preparations; 50 ng for purified proteins), mixed with 4× SDS sample loading buffer, denatured at 95°C for 10 min, and then loaded on a 7 to 10% SDS-PAGE gel. Current was applied at 60 V for 30 min and at 150 V until the dye front reached the bottom of the gel. Proteins were transferred onto an activated 0.45- μ m polyvinylidene difluoride (PVDF) membrane in cold 1× transfer buffer at 100 V for 2 h.

Membranes were blocked with 5% nonfat milk in Tris-buffered saline with 0.1% Tween (TBS-T). Aap A- or B-domain antiserum (23) was diluted 1:100,000 in 5% nonfat milk. Alkaline phosphatase (AP)-conjugated mouse anti-rabbit IgG (Jackson ImmunoResearch, West Grove, PA) was diluted 1:25,000. Blots were developed with enhanced chemifluorescence (ECF) substrate (GE Healthcare Life Sciences; Piscataway, NJ) and visualized on a Typhoon FLA 7000 laser scanner (GE Healthcare Life Sciences).

Collection of corneocytes. Sheets of corneocytes were collected by applying adhesive discs (D-Squame skin indicator D232; CuDerm Corp., Dallas, TX) with a 12.7-mm-diameter sensing area, on the inner forearm of healthy human volunteers with no history or physical signs of dermatological disease. Corneocytes were collected from the selected area after removal of the topmost epidermal layer using a regular adhesive tape and subsequent topical application of isopropyl alcohol with prep pads for sterilization. The outermost layers of the stratum corneum of the forearm were chosen for our experiments, as mature and rigid cornified envelopes were detected in the upper layers, in contrast to immature and fragile cornified envelopes from the deeper layers of stratum corneum (66).

Labeling of corneocytes. The following rhodamine-labeled lectins were used at a final concentration of 20 μ g/ml in PBS to label corneocytes: concanavalin A (ConA) recognizes α -D-mannose (Man) and α -D-glucose (Glc), *Dolichos biflorus* (DBA) and soybean agglutinin (SBA) recognize *N*-acetylgalactosamine (GalNAc), peanut agglutinin (PNA) recognizes galactose β (1,3)-linked *N*-acetylgalactosamine (Gal β 3GalNAc), *Ricinus communis* I (RCA I) recognizes β -D-galactose (Gal), *Ulex europaeus* I agglutinin (UEA I) recognizes α -L-fucose (Fuc), and wheat germ agglutinin (WGA) recognizes *N*-acetylglucosamine (GlcNAc). The above-listed lectins were purchased from Vector Laboratories (Burlingame, CA). *Sambucus nigra* lectin (SNA/EBL I) that recognizes α -(2,6)-linked sialic acid (Sia), *Maackia amurensis* lectin (MAA/MAL I) that recognizes α -(2,3)-linked sialic acid (Sia α 2-3Gal β 1-4GlcNAc), and *Maackia amurensis* lectin (MAA/MAL II) that recognizes Sia α 2-3Gal β 1-3GalNAc were purchased from GlycoMatrix (Dublin, Ohio). Corneocyte discs, with or without deglycosylation treatment of the corneocyte surfaces (see below), were incubated for 1 h, followed by removal of the stain and washing three times in PBS, prior to confocal imaging.

For visualization of cytokeratin-10 and loricrin labeling on the corneocytes, corneocyte slides were incubated with 10 μ g/ml rabbit polyclonal anti-cytokeratin-10 IgG (Abcam, Cambridge, MA) or rabbit polyclonal anti-loricrin IgG (Abcam) primary antibodies for 1 h. This was followed by incubation with Alexa Fluor 555-conjugated goat anti-rabbit IgG (Thermo Scientific) secondary antibody and subsequent confocal microscopy imaging.

Optimization of the corneocyte binding assay. The corneocyte binding assay was optimized based on previously published methods (67–70), with modifications. For optimization, the effects of time and bacterial concentration were tested on corneocytes collected on 22-mm-diameter adhesive discs (D100 D-Squame standard sampling discs; CuDerm Corp.). Briefly, *S. epidermidis* 1457 cells grown to an exponential phase (OD₆₀₀ ~0.7) were harvested, suspended in sterile PBS, and adjusted to an OD₆₀₀ of 0.15, 1.0, or 1.5. An OD₆₀₀ of 0.15 was found to correlate with ~10⁷ CFU/ml, an OD₆₀₀ of 1.0 with ~10⁸ CFU/ml, and an OD₆₀₀ of 1.5 with ~10⁹ CFU/ml. Each corneocyte sample disc was inoculated with one of three concentrations of bacterial suspension and incubated for one of three different time periods (45, 90, or 180 min). For incubation, the discs were placed with the corneocyte surface up in a small petri dish, and 500 μ l of each bacterial suspension was placed over the corneocyte layer. Following incubation, the samples were rinsed with PBS 3 times by pipetting and stained with crystal violet for 10 s. Excess stain was removed by rinsing with running water for 10 s, and the discs were then attached to glass microscope slides using transparent glue. The slides were allowed to air dry prior to microscopic examination using light microscopy. An OD₆₀₀ of 0.15 was the chosen bacterial suspension

concentration for incubation, due to visibly less clumping observed at this OD. Similarly, 45 min was chosen for the incubation, as 90- and 180-min incubation times resulted in more clumping.

Corneocyte binding assay. Overnight cultures of strains transduced with the green fluorescent protein (GFP)-expressing plasmid pCM29 were grown in 5 ml TSB containing 10 μ g/ml chloramphenicol with shaking at 250 rpm at 37°C for 16 h. Fresh TSB (12.5 ml in a 125-ml flask) was inoculated at an OD₆₀₀ of 0.1, and the cultures were grown to the exponential phase at 37°C with shaking at 250 rpm until they reached an OD₆₀₀ of ~0.7. Cells were collected by centrifugation at 5,000 rpm for 5 min at 4°C, and the pellet was washed three times with 1 ml 1 × PBS (Dulbecco's PBS, no calcium, no magnesium). The final bacterial suspension was adjusted to an OD₆₀₀ of 0.15, corresponding to ~10⁷ CFU/ml in PBS. A 300- μ l aliquot of the OD-adjusted suspension was pipetted onto D232 D-Squame discs with adhered corneocytes to form a meniscus and incubated at 37°C for 45 min in a moist chamber. After incubation, the discs were washed with 1 × PBS three times by vigorous pipetting and air dried. A cover slip was placed for imaging using confocal laser scanning microscopy.

Binding inhibition assays. For binding inhibition assays using antibodies, 300 μ l of exponential-phase bacteria (grown and harvested as above), adjusted to an OD₆₀₀ of 0.15, was preincubated with 1:10,000 dilution of anti-Aap A-domain (anti-AapA) or anti-Aap B-domain (anti-AapB) antisera (kindly provided by Holger Rohde) in PBS for 1 h at 37°C. In addition, further dilutions of the anti-AapA antibody were used at 1:10,000, 1:20,000, 1:40,000, 1:80,000, and 1:160,000. Further anti-AapB antibody dilutions were also used at 1:625, 1:1,250, 1:2,500, 1:5,000, and 1:10,000. These additional dilutions of both anti-AapA and anti-AapB antibody were added to 300 μ l of bacterial cell suspension for 1 h at 37°C. For anti-polysaccharide intercellular adhesin (PIA), a 1:2,500 dilution was used. The corneocyte binding assay was performed thereafter, as described above. For the blocking assay using recombinant proteins, corneocyte-containing discs were preincubated for 20 min with 300 μ l each recombinant Aap domain proteins diluted in PBS to give final concentrations of 0, 0.25, 0.5, 1.0, 5.0, and 10 μ M for each protein. Subsequently, the corneocyte binding assay was performed with addition of bacteria to the suspension at a final OD₆₀₀ of 0.15.

Deglycosylation of corneocyte surfaces was performed in which each corneocyte disc was incubated with one of the following deglycosylases—PNGaseF, O-glycosidase, α 2-3,6,8 neuraminidase, β 1-4 galactosidase S, α 1-3,4 fucosidase, β -N-acetylglucosaminidase S, or α 1-2,3 mannosidase (NEB)—for 24 h in a 37°C moist chamber, according to the manufacturer's instructions. This was followed by complete removal of the incubated enzymes, washing with PBS, and performing the corneocyte binding assay, as described above.

Inhibition of bacterial binding using antibodies against cytokeratin-10 and loricrin was performed, in which corneocytes were preincubated separately with 10 μ g/ml rabbit polyclonal anti-cytokeratin-10 IgG (Abcam) and rabbit polyclonal anti-loricrin IgG (Abcam) antibodies for 1 h at 37°C in blocking buffer (1% bovine serum albumin [BSA]) prior to incubation with bacteria.

Image acquisition and bacterial counting after corneocyte binding assay. Images were acquired by confocal laser scanning microscopy using an LSM 710 confocal microscope (Zeiss; Jena, Germany). GFP-expressing bacterial cells were observed with an oil immersion objective (Plan-Apochromat 63 × / 1.40 oil differential interference contrast) using a maximum excitation wavelength (λ_{ex}) of 488 nm and a maximum emission wavelength (λ_{em}) of 542 nm. Additionally, the nonlabeled corneocyte sheets from the same view field were simultaneously imaged using phase contrast optics. For quantification of adherent bacteria on each disc, 10 images of 89.8 μ m × 89.8 μ m microscopic fields containing unlabeled confluent corneocytes were captured at 63 × 1.5 magnification, superimposing both the fluorescence and phase contrast image. These fields were randomly selected, and any field in which corneocytes were either not confluent or for which the entire area could not be brought into sharp focus was rejected. In the case of rhodamine-labeled corneocytes, an λ_{ex} of 553 nm and an λ_{em} 627 nm were used for visualization.

Quantitative analysis of the number of adherent bacteria was performed using ImageJ v. 10.0 (NIH, Bethesda, MD). The images captured by the fluorescence channel, which contained the GFP signals (GFP-expressing bacteria), were converted from RGB to grayscale in ImageJ. For automated identification of bacteria in each image, thresholding of the image was accomplished by filtering within the hue-saturation-brightness (HSB) color space using the default mode. Subsequently, image noise was removed using "despeckle," brightness and contrast adjusted to make the bacterial cells more distinguishable from the background. The image was converted to a mask based on the set threshold to produce binary images with inverted lookup tables (LUTs), and "watershed" was used to create segmentation from one another in the case of clustered bacterial cells. The identified bacterial cells were finally counted using "analyze particles." The pixel counts for each circular area, as well as the average clump size within the area, were automatically entered into spreadsheet format by the software. For each strain tested, the number of adherent bacteria from all of the fields was plotted using GraphPad Prism 8. The mean number of adherent bacteria for each mutant was calculated along with standard error of the mean (SEM). Comparisons between individual mutants were performed by two-tailed unpaired Student's *t* test with 95% confidence intervals. A *P* value of <0.05 was considered to be significant in each case.

SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

FIG S1, TIF file, 0.8 MB.

FIG S2, PDF file, 0.8 MB.

FIG S3, TIF file, 1.5 MB.

FIG S4, JPG file, 0.5 MB.

TABLE S1, DOCX file, 0.04 MB.

TABLE S2, DOCX file, 0.02 MB.

TABLE S3, DOCX file, 0.02 MB.

ACKNOWLEDGMENTS

We thank Steven Carson at the University of Nebraska Medical Center for helpful discussions about the direction of this project. We thank Luke D. Handke for participation in review of the manuscript and for his suggestions. We also thank Michael Olson for construction of the 1457 Δ srtA mutant.

This work was supported by grants from the National Institutes of Health/National Institute of Allergy and Infectious Diseases (P01 AI083211 to P.D.F. and A.R.H. and R01 AI153185 to A.R.H.).

REFERENCES

- Candi E, Schmidt R, Melino G. 2005. The cornified envelope: a model of cell death in the skin. *Nat Rev Mol Cell Biol* 6:328–340. <https://doi.org/10.1038/nrm1619>.
- Stacy A, Belkaid Y. 2019. Microbial guardians of skin health. *Science* 363:227–228. <https://doi.org/10.1126/science.aat4326>.
- Byrd AL, Belkaid Y, Segre JA. 2018. The human skin microbiome. *Nat Rev Microbiol* 16:143–155. <https://doi.org/10.1038/nrmicro.2017.157>.
- Grice EA, Segre JA. 2011. The skin microbiome. *Nat Rev Microbiol* 9:244–253. <https://doi.org/10.1038/nrmicro2537>.
- Belkaid Y, Tamoutounour S. 2016. The influence of skin microorganisms on cutaneous immunity. *Nat Rev Immunol* 16:353–366. <https://doi.org/10.1038/nri.2016.48>.
- Kong HH, Oh J, Deming C, Conlan S, Grice EA, Beatson MA, Nomicos E, Polley EC, Komarow HD, Program NCS, Murray PR, Turner ML, Segre JA. 2012. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. *Genome Res* 22:850–859. <https://doi.org/10.1101/gr.131029.111>.
- Costello EK, Lauber CL, Hamady M, Fierer N, Gordon JI, Knight R. 2009. Bacterial community variation in human body habitats across space and time. *Science* 326:1694–1697. <https://doi.org/10.1126/science.1177486>.
- Grice EA, Kong HH, Conlan S, Deming CB, Davis J, Young AC, Program NCS, Bouffard GG, Blakesley RW, Murray PR, Green ED, Turner ML, Segre JA. 2009. Topographical and temporal diversity of the human skin microbiome. *Science* 324:1190–1192. <https://doi.org/10.1126/science.1171700>.
- Iwase T, Uehara Y, Shinji H, Tajima A, Seo H, Takada K, Agata T, Mizunoe Y. 2010. *Staphylococcus epidermidis* Esp inhibits *Staphylococcus aureus* biofilm formation and nasal colonization. *Nature* 465:346–349. <https://doi.org/10.1038/nature09074>.
- Sugimoto S, Iwamoto T, Takada K, Okuda K, Tajima A, Iwase T, Mizunoe Y. 2013. *Staphylococcus epidermidis* Esp degrades specific proteins associated with *Staphylococcus aureus* biofilm formation and host-pathogen interaction. *J Bacteriol* 195:1645–1655. <https://doi.org/10.1128/JB.01672-12>.
- Zipperer A, Konnerth MC, Laux C, Berscheid A, Janek D, Weidenmaier C, Burian M, Schilling NA, Slavetinsky C, Marschal M, Willmann M, Kalbacher H, Schitteck B, Brotz-Oesterhelt H, Grond S, Peschel A, Krismer B. 2016. Human commensals producing a novel antibiotic impair pathogen colonization. *Nature* 535:511–516. <https://doi.org/10.1038/nature18634>.
- Nakatsuji T, Chen TH, Narala S, Chun KA, Two AM, Yun T, Shafiq F, Kotol PF, Bouslimani A, Melnik AV, Latif H, Kim JN, Lockhart A, Artis K, David G, Taylor P, Streib J, Dorrestein PC, Grier A, Gill SR, Zengler K, Hata TR, Leung DY, Gallo RL. 2017. Antimicrobials from human skin commensal bacteria protect against *Staphylococcus aureus* and are deficient in atopic dermatitis. *Sci Transl Med* 9:eaah4680. <https://doi.org/10.1126/scitranslmed.aah4680>.
- Naik S, Bouladoux N, Wilhelm C, Molloy MJ, Salcedo R, Kastenmuller W, Deming C, Quinones M, Koo L, Conlan S, Spencer S, Hall JA, Dzutssev A, Kong H, Campbell DJ, Trinchieri G, Segre JA, Belkaid Y. 2012. Compartmentalized control of skin immunity by resident commensals. *Science* 337:1115–1119. <https://doi.org/10.1126/science.1225152>.
- Naik S, Bouladoux N, Linehan JL, Han SJ, Harrison OJ, Wilhelm C, Conlan S, Himmelfarb S, Byrd AL, Deming C, Quinones M, Brenchley JM, Kong HH, Tussiwand R, Murphy KM, Merad M, Segre JA, Belkaid Y. 2015. Commensal dendritic-cell interaction specifies a unique protective skin immune signature. *Nature* 520:104–108. <https://doi.org/10.1038/nature14052>.
- Stones DH, Krachler AM. 2016. Against the tide: the role of bacterial adhesion in host colonization. *Biochem Soc Trans* 44:1571–1580. <https://doi.org/10.1042/BST20160186>.
- Feuillie C, Vitry P, McAleer MA, Kezic S, Irvine AD, Geoghegan JA, Dufrene YF. 2018. Adhesion of *Staphylococcus aureus* to corneocytes from atopic dermatitis patients is controlled by natural moisturizing factor levels. *mBio* 9:e01184-18. <https://doi.org/10.1128/mBio.01184-18>.
- Fleury OM, McAleer MA, Feuillie C, Formosa-Dague C, Sansevere E, Bennett DE, Towell AM, McLean WHI, Kezic S, Robinson DA, Fallon PG, Foster TJ, Dufrene YF, Irvine AD, Geoghegan JA. 2017. Clumping factor B promotes adhesion of *Staphylococcus aureus* to corneocytes in atopic dermatitis. *Infect Immun* 85:e00994-16. <https://doi.org/10.1128/IAI.00994-16>.
- Bitschar K, Staudenmaier L, Klink L, Focken J, Sauer B, Fehrenbacher B, Herster F, Bittner Z, Bleul L, Schaller M, Wolz C, Weber ANR, Peschel A, Schitteck B. 2020. *Staphylococcus aureus* skin colonization is enhanced by the interaction of neutrophil extracellular traps with keratinocytes. *J Invest Dermatol* 140:1054–1065.e4. <https://doi.org/10.1016/j.jid.2019.10.017>.
- Edslev SM, Agner T, Andersen PS. 2020. Skin microbiome in atopic dermatitis. *Acta Derm Venereol* 100:adv00164. <https://doi.org/10.2340/00015555-3514>.
- Foster TJ. 2020. Surface proteins of *Staphylococcus epidermidis*. *Front Microbiol* 11:1829. <https://doi.org/10.3389/fmicb.2020.01829>.
- Speziale P, Pietrocola G, Foster TJ, Geoghegan JA. 2014. Protein-based biofilm matrices in staphylococci. *Front Cell Infect Microbiol* 4:171. <https://doi.org/10.3389/fcimb.2014.00171>.
- Foster TJ, Geoghegan JA, Ganesh VK, Hook M. 2014. Adhesion, invasion and evasion: the many functions of the surface proteins of *Staphylococcus aureus*. *Nat Rev Microbiol* 12:49–62. <https://doi.org/10.1038/nrmicro3161>.
- Rohde H, Burandt EC, Siemssen N, Frommelt L, Burdelski C, Wurster S, Scherpe S, Davies AP, Harris LG, Horstkotte MA, Knobloch JK, Ragnath C, Kaplan JB, Mack D. 2007. Polysaccharide intercellular adhesion or protein factors in biofilm accumulation of *Staphylococcus epidermidis* and *Staphylococcus aureus* isolated from prosthetic hip and knee joint infections. *Biomaterials* 28:1711–1720. <https://doi.org/10.1016/j.biomaterials.2006.11.046>.
- Schaeffer CR, Hoang TN, Sudbeck CM, Alawi M, Tolo IE, Robinson DA, Horswill AR, Rohde H, Fey PD. 2016. Versatility of biofilm matrix molecules in *Staphylococcus epidermidis* clinical isolates and importance of polysaccharide intercellular adhesion expression during high shear stress. *mSphere* 1:e00165-16. <https://doi.org/10.1128/mSphere.00165-16>.
- Gotz F. 2002. *Staphylococcus* and biofilms. *Mol Microbiol* 43:1367–1378. <https://doi.org/10.1046/j.1365-2958.2002.02827.x>.
- Schumacher-Perdreau F, Heilmann C, Peters G, Gotz F, Pulverer G. 1994. Comparative analysis of a biofilm-forming *Staphylococcus epidermidis* strain and its adhesion-positive, accumulation-negative mutant M7. *FEMS Microbiol Lett* 117:71–78. <https://doi.org/10.1111/j.1574-6968.1994.tb06744.x>.
- Hussain M, Herrmann M, von Eiff C, Perdreau-Remington F, Peters G. 1997. A 140-kilodalton extracellular protein is essential for the accumulation of *Staphylococcus epidermidis* strains on surfaces. *Infect Immun* 65:519–524. <https://doi.org/10.1128/iai.65.2.519-524.1997>.

28. Banner MA, Cunniffe JG, Macintosh RL, Foster TJ, Rohde H, Mack D, Hoyes E, Derrick J, Upton M, Handley PS. 2007. Localized tufts of fibrils on *Staphylococcus epidermidis* NCTC 11047 are comprised of the accumulation-associated protein. *J Bacteriol* 189:2793–2804. <https://doi.org/10.1128/JB.00952-06>.
29. Conrady DG, Wilson JJ, Herr AB. 2013. Structural basis for Zn²⁺-dependent intercellular adhesion in staphylococcal biofilms. *Proc Natl Acad Sci U S A* 110:E202–11. <https://doi.org/10.1073/pnas.1208134110>.
30. Gruszka DT, Wojdyla JA, Bingham RJ, Turkenburg JP, Manfield IW, Steward A, Leech AP, Geoghegan JA, Foster TJ, Clarke J, Potts JR. 2012. Staphylococcal biofilm-forming protein has a contiguous rod-like structure. *Proc Natl Acad Sci U S A* 109:E1011–E1018. <https://doi.org/10.1073/pnas.1119456109>.
31. Bowden MG, Chen W, Singvall J, Xu Y, Peacock SJ, Valtulina V, Speziale P, Höök M. 2005. Identification and preliminary characterization of cell-wall-anchored proteins of *Staphylococcus epidermidis*. *Microbiology* 151:1453–1464. <https://doi.org/10.1099/mic.0.27534-0>.
32. Conlon BP, Geoghegan JA, Waters EM, McCarthy H, Rowe SE, Davies JR, Schaeffer CR, Foster TJ, Fey PD, O’Gara JP. 2014. Role for the A domain of unprocessed accumulation-associated protein (Aap) in the attachment phase of the *Staphylococcus epidermidis* biofilm phenotype. *J Bacteriol* 196:4268–4275. <https://doi.org/10.1128/JB.01946-14>.
33. Schaeffer CR, Woods KM, Longo GM, Kiedrowski MR, Paharik AE, Buttner H, Christner M, Boissy RJ, Horswill AR, Rohde H, Fey PD. 2015. Accumulation-associated protein enhances *Staphylococcus epidermidis* biofilm formation under dynamic conditions and is required for infection in a rat catheter model. *Infect Immun* 83:214–226. <https://doi.org/10.1128/IAI.02177-14>.
34. Paharik AE, Kotasinska M, Both A, Hoang TN, Buttner H, Roy P, Fey PD, Horswill AR, Rohde H. 2017. The metalloprotease SepA governs processing of accumulation-associated protein and shapes intercellular adhesive surface properties in *Staphylococcus epidermidis*. *Mol Microbiol* 103:860–874. <https://doi.org/10.1111/mmi.13594>.
35. Rohde H, Burdelski C, Bartscht K, Hussain M, Buck F, Horstkotte MA, Knobloch JK, Heilmann C, Herrmann M, Mack D. 2005. Induction of *Staphylococcus epidermidis* biofilm formation via proteolytic processing of the accumulation-associated protein by staphylococcal and host proteases. *Mol Microbiol* 55:1883–1895. <https://doi.org/10.1111/j.1365-2958.2005.04515.x>.
36. Bateman A, Holden MT, Yeats C. 2005. The G5 domain: a potential N-acetylglucosamine recognition domain involved in biofilm formation. *Bioinformatics* 21:1301–1303. <https://doi.org/10.1093/bioinformatics/bti206>.
37. Conrady DG, Brescia CC, Horii K, Weiss AA, Hassett DJ, Herr AB. 2008. A zinc-dependent adhesion module is responsible for intercellular adhesion in staphylococcal biofilms. *Proc Natl Acad Sci U S A* 105:19456–19461. <https://doi.org/10.1073/pnas.0807717105>.
38. Macintosh RL, Brittan JL, Bhattacharya R, Jenkinson HF, Derrick J, Upton M, Handley PS. 2009. The terminal A domain of the fibrillar accumulation-associated protein (Aap) of *Staphylococcus epidermidis* mediates adhesion to human corneocytes. *J Bacteriol* 191:7007–7016. <https://doi.org/10.1128/JB.00764-09>.
39. Trivedi S, Uhlemann AC, Herman-Bausier P, Sullivan SB, Sowash MG, Flores EY, Khan SD, Dufrene YF, Lowy FD. 2017. The surface protein SdrF mediates *Staphylococcus epidermidis* adherence to keratin. *J Infect Dis* 215:1846–1854. <https://doi.org/10.1093/infdis/jix213>.
40. Hoang TM, Zhou C, Lindgren JK, Galac MR, Corey B, Endres JE, Olson ME, Fey PD. 2019. Transcriptional regulation of *icaADBC* by both *IcaR* and *TcaR* in *Staphylococcus epidermidis*. *J Bacteriol* 201:e00524-18. <https://doi.org/10.1128/JB.00524-18>.
41. Mazmanian SK, Ton-That H, Schneewind O. 2001. Sortase-catalysed anchoring of surface proteins to the cell wall of *Staphylococcus aureus*. *Mol Microbiol* 40:1049–1057. <https://doi.org/10.1046/j.1365-2958.2001.02411.x>.
42. Roche FM, Meehan M, Foster TJ. 2003. The *Staphylococcus aureus* surface protein SasG and its homologues promote bacterial adherence to human desquamated nasal epithelial cells. *Microbiology* 149:2759–2767. <https://doi.org/10.1099/mic.0.26412-0>.
43. Yarawsky AE, English LR, Whitten ST, Herr AB. 2017. The Proline/glycine-rich region of the biofilm adhesion protein Aap forms an extended stalk that resists compaction. *J Mol Biol* 429:261–279. <https://doi.org/10.1016/j.jmb.2016.11.017>.
44. Varki A. 2011. Evolutionary forces shaping the Golgi glycosylation machinery: why cell surface glycans are universal to living cells. *Cold Spring Harb Perspect Biol* 3:a005462. <https://doi.org/10.1101/cshperspect.a005462>.
45. Schnaar RL. 2015. Glycans and glycan-binding proteins in immune regulation: a concise introduction to glycobiology for the allergist. *J Allergy Clin Immunol* 135:609–615. <https://doi.org/10.1016/j.jaci.2014.10.057>.
46. Tang L, Chen X, Zhang X, Guo Y, Su J, Zhang J, Peng C, Chen X. 2019. N-Glycosylation in progression of skin cancer. *Med Oncol* 36. <https://doi.org/10.1007/s12032-019-1270-4>.
47. Danzberger J, Donovan M, Rankl C, Zhu R, Vivic S, Baltenneck C, Enea R, Hinterdorfer P, Luengo GS. 2018. Glycan distribution and density in native skin’s stratum corneum. *Skin Res Technol* 24:450–458. <https://doi.org/10.1111/srt.12453>.
48. Crosby HA, Schlievert PM, Merriman JA, King JM, Salgado-Pabon W, Horswill AR. 2016. The *Staphylococcus aureus* global regulator MgrA modulates clumping and virulence by controlling surface protein expression. *PLoS Pathog* 12:e1005604. <https://doi.org/10.1371/journal.ppat.1005604>.
49. Nakatsuji T, Chen TH, Butcher AM, Trzoss LL, Nam SJ, Shirakawa KT, Zhou W, Oh J, Otto M, Fenical W, Gallo RL. 2018. A commensal strain of *Staphylococcus epidermidis* protects against skin neoplasia. *Sci Adv* 4:eaa04502. <https://doi.org/10.1126/sciadv.aao4502>.
50. Varki A, Cummings RD, Esko JD, Stanley P, Hart GW, Aebi M, Darvill AG, Kinoshita T, Packer NH, Prestegard JH, Schnaar RL, Seeberger PH (ed). 2015. Essentials of glycobiology. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
51. Ilver D, Johansson P, Miller-Podraza H, Nyholm PG, Teneberg S, Karlsson KA. 2003. Bacterium-host protein-carbohydrate interactions. *Methods Enzymol* 363:134–157. [https://doi.org/10.1016/S0076-6879\(03\)01049-8](https://doi.org/10.1016/S0076-6879(03)01049-8).
52. Gonzalez T, Stevens ML, Kyzyl AB, Alarcon R, He H, Kroner JW, Spagna D, Grashel B, Sidler E, Martin LJ, Biagini Myers JM, Hershey K, Herr AB. 2021. Biofilm propensity of *Staphylococcus aureus* skin isolates is associated with increased atopic dermatitis severity and barrier dysfunction in the MPAACH pediatric cohort. *Allergy* 76:302–312. <https://doi.org/10.1111/all.14489>.
53. Kwiecinski JM, Crosby HA, Valotteau C, Hippensteel JA, Nayak MK, Chauhan AK, Schmidt EP, Dufrene YF, Horswill AR. 2019. *Staphylococcus aureus* adhesion in endovascular infections is controlled by the ArlRS-MgrA signaling cascade. *PLoS Pathog* 15:e1007800. <https://doi.org/10.1371/journal.ppat.1007800>.
54. Varki A. 2017. Biological roles of glycans. *Glycobiology* 27:3–49. <https://doi.org/10.1093/glycob/cww086>.
55. Mack D, Siemssen N, Laufs R. 1992. Parallel induction by glucose of adherence and a polysaccharide antigen specific for plastic-adherent *Staphylococcus epidermidis*: evidence for functional relation to intercellular adhesion. *Infect Immun* 60:2048–2057. <https://doi.org/10.1128/iai.60.5.2048-2057.1992>.
56. Studier FW. 2005. Protein production by auto-induction in high density shaking cultures. *Protein Expr Purif* 41:207–234. <https://doi.org/10.1016/j.pep.2005.01.016>.
57. Bose JL, Fey PD, Bayles KW. 2013. Genetic tools to enhance the study of gene function and regulation in *Staphylococcus aureus*. *Appl Environ Microbiol* 79:2218–2224. <https://doi.org/10.1128/AEM.00136-13>.
58. Projan SJ, Archer GL. 1989. Mobilization of the relaxable *Staphylococcus aureus* plasmid pC221 by the conjugative plasmid pG01 involves three pC221 loci. *J Bacteriol* 171:1841–1845. <https://doi.org/10.1128/jb.171.4.1841-1845.1989>.
59. Winstel V, Kuhner P, Krismer B, Peschel A, Rohde H. 2015. Transfer of plasmid DNA to clinical coagulase-negative staphylococcal pathogens by using a unique bacteriophage. *Appl Environ Microbiol* 81:2481–2488. <https://doi.org/10.1128/AEM.04190-14>.
60. Maliszewski KL, Nuxoll AS. 2014. Use of electroporation and conjugative mobilization for genetic manipulation of *Staphylococcus epidermidis*. *Methods Mol Biol* 1106:125–134. https://doi.org/10.1007/978-1-62703-736-5_11.
61. Olson ME, Horswill AR. 2014. Bacteriophage transduction in *Staphylococcus epidermidis*. *Methods Mol Biol* 1106:167–172. https://doi.org/10.1007/978-1-62703-736-5_15.
62. Bose JL. 2014. Genetic manipulation of staphylococci. *Methods Mol Biol* 1106:101–111. https://doi.org/10.1007/978-1-62703-736-5_8.
63. Handke LD, Slater SR, Conlon KM, O’Donnell ST, Olson ME, Bryant KA, Rupp ME, O’Gara JP, Fey PD. 2007. SigmaB and SarA independently regulate polysaccharide intercellular adhesion production in *Staphylococcus epidermidis*. *Can J Microbiol* 53:82–91. <https://doi.org/10.1139/w06-108>.
64. Yajjala VK, Widhelm TJ, Endres JL, Fey PD, Bayles KW. 2016. Generation of a transposon mutant library in *Staphylococcus aureus* and *Staphylococcus epidermidis* using *bursa aurealis*. *Methods Mol Biol* 1373:103–110. https://doi.org/10.1007/978-1-62703-736-5_4.
65. Goering RV, Fey PD. 2014. Pulsed field gel electrophoresis of *Staphylococcus epidermidis*. *Methods Mol Biol* 1106:55–60. https://doi.org/10.1007/978-1-62703-736-5_4.
66. Hiraio T, Denda M, Takahashi M. 2001. Identification of immature cornified envelopes in the barrier-impaired epidermis by characterization of their

- hydrophobicity and antigenicities of the components. *Exp Dermatol* 10:35–44. <https://doi.org/10.1034/j.1600-0625.2001.100105.x>.
67. Griffeth GC, Callori N, Rankin SC, Boston RC, Morris DO. 2012. Optimization of a *Staphylococcus aureus* adhesion assay for equine corneocytes. *Vet Dermatol* 23:57–60.e13. <https://doi.org/10.1111/j.1365-3164.2011.01012.x>.
68. Lu YF, McEwan NA. 2007. Staphylococcal and micrococcal adherence to canine and feline corneocytes: quantification using a simple adhesion assay. *Vet Dermatol* 18:29–35. <https://doi.org/10.1111/j.1365-3164.2007.00567.x>.
69. Latronico F, Moodley A, Nielsen SS, Guardabassi L. 2014. Enhanced adherence of methicillin-resistant *Staphylococcus pseudintermedius* sequence type 71 to canine and human corneocytes. *Vet Res* 45:70. <https://doi.org/10.1186/1297-9716-45-70>.
70. Simou C, Hill PB, Forsythe PJ, Thoday KL. 2005. Species specificity in the adherence of staphylococci to canine and human corneocytes: a preliminary study. *Vet Dermatol* 16:156–161. <https://doi.org/10.1111/j.1365-3164.2005.00452.x>.